Back to results
US 5,684,017 AGranted
Benzenesulfonylimine derivatives as inhibitors of IL-1 action
AssigneeMerrell Pharmaceuticals Inc.
InventorsBoyd L. Harrison, George Ku, Scott B. Meikrantz, Christopher R. Dalton, David M. Stemerick
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel benzenesulfonylimine derivatives and their use as inhibitors of Interleukin-1 (IL-1) action. Such inhibitors are useful in the treatment of various disease states as disclosed herein including: rheumatoid arthritis, multiple sclerosis, diabetes mellitus, atherosclerosis, septic shock and pulmonary fibrosis.
Claims7
A compound of the formula ##STR8## wherein A is NH;
- R is C.sub.1 -C.sub.6 alkyl radical of branched or straight chained or cyclic configuration, or phenyl, or substituted phenyl bearing from 1 to 3 substituents chosen independently from the group consisting of hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen, --NHC(O)CH.sub.3, amino, or hydroxy;
- Z is from 1 to 3 substituents chosen independently from the group consisting of hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, or halogen;
- Y is from 1 to 3 substituents chosen independently from the group consisting of hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, or halogen.
Dependencies are inferred from the claim text.